Figure 3

Behavioral profile evaluation (SHIRPA protocol) of animals infected with C. gattii and treated with amphotericin B (AMB), fluconazole (FLC15 and FLC150) and the combination FLC15 + AMB and FLC150 + AMB (A–E). (A) Muscle tone and strength; (B) autonomous function; (C) Reflex and sensory function (D) neuropsychiatric state; (E) motor behavior. NI (not infected); NT (Control, untreated), AMB (Amphotericin B 0.5 mg/kg/day), FLC15 (Fluconazole 15 mg/kg/day), FLC150 (Fluconazole 150 mg/kg/day) FLC15 + AMB (Fluconazole 15 mg/kg/day + Amphotericin B 0.5 mg/kg/day), FLC150 + AMB (Fluconazole 150 mg/kg/day + Amphotericin B 0.5 mg/kg/day). **P < 0.01 ***P < 0.001 (difference when compared to NT).